[1]王丽君,张锦文*,成建,等.235例细胞学阴性/高危型人乳头瘤病毒阳性患者宫颈病理结果分析[J].中国计划生育和妇产科,2017,(1):59-63.
　WANG Li-jun,ZHANG Jin-wen*,CHENG Jian,et al.Analysis of cervical pathology in 235 cytology-negative/HR - HPV positive patients[J].Chinese Journal of Family Planning & Gynecotokology,2017,(1):59-63.
点击复制

235例细胞学阴性/高危型人乳头瘤病毒阳性患者宫颈病理结果分析
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2017年1期
页码:
59-63
栏目:
论著与临床
出版日期:
2017-01-25

文章信息/Info

Title:
Analysis of cervical pathology in 235 cytology-negative/HR - HPV positive patients
作者:
王丽君; 张锦文*; 成建; 吴江平
南京医科大学附属南京妇幼保健院妇女保健科
Author(s):
WANG Li-jun;  ZHANG Jin-wen*;  CHENG Jian;  WU Jiang-ping
Department of Women Health Care， Nanjing Maternity and Child Health Hospital Affiliated Nanjing Medical University, Nanjing Jiangsu 210004，P.R.China
关键词:
宫颈细胞学; 高危型人乳头瘤病毒; 基因型; 宫颈上皮内瘤变
Keywords:
cervical cytology; HR-HPV; genotype; CIN
摘要:
目的了解宫颈细胞学和高危型人乳头瘤病毒（high risk-human papillomavirus，HR-HPV)联合检查的必要性。方法对2013年12月至2014年12月在南京医科大学附属南京妇幼保健院门诊进行妇科检查，细胞学阴性/HR-HPV阳性的235例患者进行阴道镜检查和宫颈活组织病理检查，对其结果进行分析。结果235例患者中，85例感染HPV 16/18型，宫颈上皮内瘤变（cervical intraepithelial neoplasia,CIN）≥Ⅱ级19例（2235 %）；150例感染其余各型，≥CIN Ⅱ的16例（1067 %），差异有统计学意义（P﹤005）。结论细胞学和HR-HPV联合检查提高了CIN和宫颈癌的检出率，HR-HPV 16/18的检出更有助于识别那些处于最高风险患CIN的女性，更有利于对宫颈癌的早期发现和诊治。
Abstract:
ObjectiveTo understand the necessity of the joint inspection of cervical cytology and high risk-human papilloma virus (HR-HPV). Methods235 cytology-negative/HR - HPV positive women who took gynecological examination in Nanjing Maternity and Child Health Hospital Affiliated Nanjing Medical University from December 2013 to December 2014 were selected.Colposcopy and cervical histopathological examination were carried out and the results were analyzed.ResultsIn 235 cases,85 cases were infected with HPV 16/18, and 19 cases (22.35%) were found to have cervical intraepithelial neoplasia (CIN) Ⅱ-Ⅲ,150 cases were infected with other HR-HPV types and 16 cases (10.67%) were found to have CIN Ⅱ-Ⅲ. The difference was statistically significant(P﹤005).ConclusionJoint inspection of cytology and HR-HPV improves the detection ratio of CIN and cervical cancer. The detection of HR-HPV 16/18 helps to recognize women with highest risk of CIN，and is beneficial to discover and treat cervical cancer.

参考文献/References:

［1］谢幸，苟文丽妇产科学 ［M］北京：人民卫生出版社，2013：301-304 ［2］DE SANJOS S, DIAZ M, CASTELLSAGUX, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis ［J］. The Lancet Infectious Diseases, 2007, 7(7): 453-459. ［3］YE Jing, CHENG Xiao-dong, CHEN Xiao-jing, et al. Prevalence and risk profile of cervical human papillomavirus infection in Zhejiang Province, southeast China: a population-based study ［J］. Virology Journal, 2010, 7(66): 66. ［4］CHEN Qiang, XIE Long-xu, QING Zhi-rong, et al. Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, eastern Guangdong Province of China ［J］. PLOS One, 2012, 7(2): e32149. ［5］LEE E H, UM T H, CHI H S, et al. Prevalence and distribution of human papillomavirus infection in Korean women as determined by restriction fragment mass polymorphism assay ［J］. Journal of Korean Medical Science, 2012, 27(9): 1091-1097. ［6］TAKEHARA K, TODA T, NISHIMURA T, et al. Human papillomavirus types 52 and 58 are prevalent in uterine cervical squamous lesions from Japanese women ［J］. Pathology Research International, 2011(5): 246936. ［7］MASSAD L S, EINSTEIN M H, HUH W K, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors ［J］. Journal of Lower Genital Tract Disease, 2013, 17(5 Suppl 1): 1-27. ［8］KITCHENER H C, ALMONTE M, THOMSON C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial ［J］. The Lancet Oncology, 2009, 10(7): 672-682. ［9］RONCO G, GIORGI-ROSSI P, CAROZZI F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial ［J］. The Lancet Oncology, 2010, 11(3): 249-257. ［10］RIJKAART D C, BERKHOF J, ROZENDAAL L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial［J］. The Lancet Oncology, 2012, 13(1): 78-88. ［11］COX J T, CASTLE P E, BEHRENS C M, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the Athena HPV study ［J］. American Journal of Obstetrics and Gynecology, 2013, 208(3):305. ［12］KHAN M J, CASTLE P E, LORINCZ A T, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice ［J］. Journal of the National Cancer Institute, 2005, 97(14): 1072-1079. ［13］PAENGCHIT K, KIETPEERAKOOL C, WANGCHAI Warunee, et al. Cervical pathology in cytology-negative/HPV-positive women: results from Lampang Cancer Hospital, Thailand ［J］. Asian Pacific Journal of Cancer Prevention : APJCP, 2014, 15(18): 7951-7954. ［14］WRIGHT T C, STOLER M H, SHARMA A, et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results ［J］. American Journal of Clinical Pathology, 2011, 136(4): 578-586. ［15］ALTHOFF K N, PAUL P, BURKE A E, et al. Correlates of cervicovaginal human papillomavirus detection in perimenopausal women ［J］. Journal of Women's Health (2002), 2009, 18(9): 1341-1346. ［16］GONZLEZ P, HILDESHEIM A, RODRGUEZ A C, et al. Behavioral/lifestyle and immunologic factors associated with HPV infection among women older than 45 years ［J］. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 2010, 19(12): 3044-3054. ［17］BELLO B D, SPINILLO A, ALBERIZZI P, et al. Cervical infections by multiple human papillomavirus (HPV) genotypes: Prevalence and impact on the risk of precancerous epithelial lesions ［J］. Journal of Medical Virology, 2009, 81(4): 703-712.

相似文献/References:

[1]夏晓梦,方小玲.妊娠期宫颈细胞学与阴道镜检查的特征与处理[J].中国计划生育和妇产科,2013,(01):0.
　XIA Xiao-meng,FANG Xiao-ling*.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(1):0.
[2]梅丽,李丽,刘婷婷,等.高危型HPV病毒负荷量指导CINⅠ的治疗分析[J].中国计划生育和妇产科,2013,(03):0.
　MEI Li,LI Li *,LIU Ting - ting.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(1):0.
[3]杨娟,关婷,蔡虹,等.高危型人乳头瘤病毒检测作为宫颈癌初筛手段的应用研究[J].中国计划生育和妇产科,2016,(02):0.
　YANG Juan,GUAN Ting,CAI Hong,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2016,(1):0.
[4]黄晨玲子,罗新.清除下生殖道高危型人乳头瘤病毒感染的可行性与必要性[J].中国计划生育和妇产科,2016,(09):0.
　Huang Chen-lingzi,Luo Xin,[J].Chinese Journal of Family Planning & Gynecotokology,2016,(1):0.
[5]徐惠琴.248例宫颈上皮内瘤变患者宫颈环形电切术后复发的相关危险因素分析[J].中国计划生育和妇产科,2016,(11):0.
　XU Hui-qin,[J].Chinese Journal of Family Planning & Gynecotokology,2016,(1):0.
[6]李晓林,李婧,陈龙,等.高危型人乳头瘤病毒E 6/E 7 mRNA检测在意义不明的非典型鳞状上皮细胞中的分流价值[J].中国计划生育和妇产科,2017,(2):55.
　LI Xiao-lin,LI Jing,CHEN Long,et al.Value of high-risk human papillomavirus E6 / E7 mRNA in atypical squamous cells of undetermined significance triage[J].Chinese Journal of Family Planning & Gynecotokology,2017,(1):55.
[7]李瑞琼,王晓银*.干扰素栓联合中药阴道灌洗治疗宫颈高危型人乳头瘤病毒感染疗效分析[J].中国计划生育和妇产科,2018,(5):38.
　LI Rui-qiong,WANG Xiao-yin*.Efficacy of interferon suppository combined with traditional Chinese medicine vaginal lavage in treating cervical high-risk human papilloma virus infection[J].Chinese Journal of Family Planning & Gynecotokology,2018,(1):38.
[8]赵佳,何玉霞,杜利君*.四川南充地区3 762例女性高危型人乳头瘤病毒感染结果分析[J].中国计划生育和妇产科,2018,(8):94.
　ZHAO jia,HE Yu-xia,DU Li-jun*.Analysis of 3 762 women with high-risk HPV infection in Nanchong area, Sichuan[J].Chinese Journal of Family Planning & Gynecotokology,2018,(1):94.
[9]蔡蕊.高危型人乳头瘤病毒感染与宫颈炎、宫颈癌及 癌前病变的关系研究[J].中国计划生育和妇产科,2019,(4):86.
　CAI Rui.Relationship between high-risk human papillomavirus infection and cervicitis, cervical cancer and precancerous lesions[J].Chinese Journal of Family Planning & Gynecotokology,2019,(1):86.

更新日期/Last Update: 2017-01-25